LifeSci Capital initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $117 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Promising Outlook for Praxis Precision Medicines: Buy Rating Affirmed on Strong Drug Efficacy and Financial Position
- Praxis Precision price target raised to $65 from $61 at Jefferies
- Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success
- Praxis Precision price target raised to $115 from $105 at H.C. Wainwright
- Praxis Precision Medicines Reports Promising Study Results